TMX Newsfile Cannabis Manufacturer News Releases

Psyched Wellness Highlights U.S. Federal Policy Momentum Supporting Psychedelic Sector

Thu, 23 Apr 2026 07:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - April 23, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company"), a life sciences company focused on the production and distribution of Amanita Muscaria-derived health and wellness products, today highlights recent U.S. federal policy developments supporting psychedelic research and outlines the potential implications for the sector and the Company.Recent announcements by U.S. President Donald Trump include an executive order...

City View Green Holdings Inc. Announces Non-Brokered Private Placement and Shares for Debt Settlements

Thu, 23 Apr 2026 07:17:00 -0400

Toronto, Ontario--(Newsfile Corp. - April 23, 2026) - City View Green Holdings Inc. (CSE: CVGR) (OTC Pink: CVGRF) (FSE: CVY0) (the "Company" or "City View") announces that it proposes to undertake an up to $500,000 non-brokered private placement (the "Offering") of units (each, a "Unit") to be sold at a price of $0.05 per Unit. Each Unit will consist of one common share of the Company and one common share purchase warrant. Each warrant will entitle the holder to purchase one common share of...

Delivra Health Brands Enters into Licence Agreement with Peak Processing to Manufacture and Distribute Its Topical Brand LivRelief Infused(TM)

Wed, 22 Apr 2026 17:45:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - April 22, 2026) - Delivra Health Brands Inc. (TSXV: DHB) OTCQB: DHBUF) ("Delivra Health" or the "Company"), a consumer packaged goods company uniquely positioned in the health and wellness sector, announced today that its wholly-owned subsidiary, LivCorp Inc., has entered into a licence agreement ("Licence Agreement") with Peak Processing Solutions ("Peak") (ASX: PKP), to manufacture, distribute and sell infused LivRelief™ branded topicals in...

Vext Announces Revised Date for Q4 and Fiscal 2025 Financial Results Release

Tue, 21 Apr 2026 16:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - April 21, 2026) - Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF) ("Vext" or the "Company") a U.S.-based cannabis operator in Arizona and Ohio, today announced that further to its previous disclosure regarding the timing of its fourth quarter and full year 2025 financial results release and conference call, the Company now expects to release its financial results for the period ended December 31, 2025, before market open on Wednesday, April 29, 2026....

Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart

Tue, 14 Apr 2026 07:27:00 -0400

Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that Cardiol's President and Chief Executive Officer, David Elsley, will participate in a live interview on X with Barchart.com ("Barchart") today at 12:00 p.m. EDT.Interview Topics:The ongoing...

Akanda Corp. Announces Reverse Stock Split

Thu, 09 Apr 2026 08:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - April 9, 2026) - Akanda Corp. (NASDAQ: AKAN) (the "Company" or "Akanda"), today announced that it expects to implement a 1-for-4.5 reverse stock split of the Company's common shares effective April 13, 2026. The reverse stock split was previously approved by the Company's shareholders on November 28, 2025 and Board of Directors on March 23, 2026 and will begin trading on an adjusted basis giving effect to the reverse stock split at the opening of market on...

FloraWorks Announces TruCBN(TM) Readiness for the CMS Substance Access BEI Program with Full Clinical and Safety Substantiation

Thu, 09 Apr 2026 08:00:00 -0400

Portland, Oregon--(Newsfile Corp. - April 9, 2026) - FloraWorks today announced that TruCBN™ 50 mg softgels are available to healthcare organizations evaluating sleep-focused hemp products for the CMS Substance Access Beneficiary Engagement Incentive (BEI) program.In a published 1,020-person randomized, double-blind, placebo-controlled clinical trial, TruCBN™ 50 mg dose demonstrated statistically significant improvement in sleep quality.Real-world evidence has also shown longer sleep duration,...

Akanda Adjourns Shareholder Meeting

Tue, 07 Apr 2026 08:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - April 7, 2026) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company") today announced that on March 31, 2026, it convened and subsequently adjourned its Special Meeting of Shareholders (the "Meeting") without transacting any business due to the absence of a quorum.The Meeting has been adjourned and will be reconvened in person in Toronto, Ontario on Monday, April 27, 2026 at 10:00 a.m. (Eastern Time). The adjournment provides the Company with additional...

Simply Solventless Provides Restructuring Update, Including Expected Timing, and Announces Management Change

Mon, 06 Apr 2026 06:00:00 -0400

Not for distribution to U.S. news wire services or for dissemination in the United States.Calgary, Alberta--(Newsfile Corp. - April 6, 2026) - Simply Solventless Concentrates Ltd. (TSXV: HASH) ("SSC") is pleased to provide an update regarding the previously announced restructuring of Massive Hash Factory Ltd. ("MHF"), CannMart Inc. ("CannMart"), and ANC Inc. ("ANC") (and collectively with MHF and CannMart, the "CCAA Applicants") ("Restructuring") (links: February 27, 2026 News Release, March 2,...

Cardiol Therapeutics Announces Year-End 2025 Update on Operations

Wed, 01 Apr 2026 07:27:00 -0400

Initiated pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and surpassed 50% patient enrollment, with full enrollment expected in Q2 2026.Reported positive Phase II ARCHER data showing CardiolRx™ significantly reduced left ventricular mass in patients with acute myocarditis; results published in ESC Heart Failure.Advanced CRD-38 program, a novel next generation drug intended for use in heart failure and other inflammatory heart diseases, to support an Investigational New...